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ABSTRACT
Background. Bisphosphonate-related osteonecrosis of the
jaw (BRONJ) is a well-documented adverse event from
treatment with nitrogen-containing bisphosphonates
(NBPs). During a preliminary histomorphometric study
aimed at assessing the rate of bone remodeling in the jaws
of patient with surgically resected BRONJ, we found a de-
fect of bone mineralization (unpublished data). We hy-
pothesized that osteomalacia could be a risk factor for
BRONJ in patients taking NBPs. Therefore, we looked for
static and dynamic histomorphometric evidence of osteo-
malacia in biopsies from subjects with and without
BRONJ.
Methods. This case-control study used histomorphomet-
ric analysis of bone specimens of patients using NBPs (22
patients with BRONJ and 21 patients without BRONJ)
who required oral surgical interventions for the treatment/
prevention of osteonecrosis. Patients were given tetracy-
cline hydrochloride according to a standardized protocol
before taking bone biopsies from their jaws. Biopsies with
evidence of osteomyelitis or necrosis at histology were ex-
cluded from the study. Osteomalacia was defined as a min-
eralization lag time >100 days, a corrected mean osteoid
thickness>12.5 mm, and an osteoid volume>10%.
Results. In all, 77% of patients with BRONJ were os-
teomalacic compared with 5% of patients without
BRONJ, according to histomorphometry. Because os-
teomalacia was found almost exclusively in NBP users
with BRONJ, this is likely to be a generalized process in
which the use of NBPs further deteriorates mechanisms
of bone repair.
Conclusions. Osteomalacia represents a new and previ-
ously unreported risk factor for disease development. This
finding may contribute to a better understanding of the
pathogenesis of this disease and help with the development
of strategies to increase the safety of NBP administration.
The Oncologist 2012;17:000–000
INTRODUCTION
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a
well-documented adverse event of treatment with nitrogen-
containing bisphosphonates (NBPs) [1–3].
Several several risk factors for BRONJ have been identi-
fied, including type and cumulative dose of NBP, tooth extrac-
tion, and use of dentures [4]. However, its pathogenesis is not
fully understood. Suppression of osteoclast-mediated bone re-
modelling and angiogenesis have been suggested to play a ma-
jor pathogenetic role in BRONJ [5, 6].
During a preliminary histomorphometric study aimed at
evaluating the rate of bone remodelling in the jaws of patients
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with surgically resected BRONJ, we found a defect of bone
mineralization in all jaws (unpublished data). In agreement
with a study reporting a higher frequency of BRONJ in zole-
dronate-treated patients with persistently low serum calcium
and secondary hyperparathyroidism [7], we hypothesized that
osteomalacia could be a risk factor for BRONJ in patients tak-
ing NBPs.
Because osteomalacia is essentially a histological diagno-
sis and may exist in the absence of biochemical and radiolog-
ical abnormalities [8], we performed a case-control study to
evaluate the static and dynamic histomorphometric evidence
of osteomalacia in biopsies from subjects treated with NBP
with or without BRONJ.
PATIENTS AND METHODS
A case-control study was performed between July 2007 and
July 2009 by enrolling cases and controls from two cohort
studies running at the maxillofacial units of Verona and Pa-
dova Universities [9, 10]. Patients in the BRONJ group were
treated with NBP for a confirmed diagnosis of osteonecrosis of
the mandible or maxilla [3]. They were candidates for surgical
resection of the diseased jaw or for tooth extraction in the dis-
eased jawbone without signs of BRONJ as a part of a preven-
tive protocol of BRONJ [10]. Patients in the control group
were treated with NBP without clinical and radiological signs
of BRONJ [3]. They were candidates for tooth extraction as a
part of a preventive protocol of BRONJ [10]. Vitamin D sup-
plementation during NBP treatment was a reason for exclu-
sion. The study protocol was approved by the local ethical
committee (resolution 1428–07), and all patients gave written
informed consent.
Clinical and Radiological Assessment
NBP usage was recorded in terms of type, dosage, and dura-
tion. Images of the oral cavity were taken using a digital cam-
era (Nikon Finepix S1 Pro; Nikon, Tokyo, Japan). All patients
underwent panoramic radiography before bone sampling.
Cases underwent also spiral computed tomography and mag-
netic resonance imaging to define surgical resection margins
[9].
Bone Sampling
Patients were given tetracycline hydrochloride, a fluoro-
chrome incorporated at the bone mineralization front, at a stan-
dard dose of 500 mg twice daily for 2 days [11]. The same dose
was repeated 12 days after the first dose. Surgery and bone
sampling were performed from 5 to 7 days after administration
of the second dose of tetracycline. In cases, bone sampling was
performed on each resection margin to include the entire cross-
sectional area of the mandible or maxilla [12]. Alternatively,
4-mm width core bone biopsies containing buccal and lingual
cortical plates with cancellous bone were obtained from the al-
veolar process of the nondiseased jaw using a trephine dental
drill under saline irrigation. In the control group, 4-mm width
core bone biopsies containing buccal and lingual cortical
plates with cancellous bone were obtained as described for the
BRONJ group.
Bone samples were fixed in 70% ethanol and embedded in
methyl-methacrylate resin (Merck 800590; Merck, Darmstadt,
Germany). Bone sections were cut with a microtome (Polycut
S; Leica Microsystems, Wetzlar, Germany) equipped with a
carbide-tungsten blade. Serial sections of 5-m were cut from
each specimen and stained with hematoxylin-eosin (HE) for
histological examination. Resin-embedded bone blocks were
then cut to obtain 8-m section, which were stained with Gold-
ner’s trichrome and mounted on microscope slides for histo-
morphometric evaluation. Such 8-m sections were obtained
from three different levels of methyl-methacrylate block and
were separated by a thickness of 250 m. A total of three to
five sections from each level were left unstained for the mea-
surement of fluorescent labelling.
Histological Examination
Histological examination was performed using an optical mi-
croscope (Leica DFC 280; Leica Microsystems, Wetzlar, Ger-
many). A single experienced pathologist (B.S.), who was
blinded to the clinical status of the patients, examined HE sec-
tions looking for signs of osteomyelitis and/or osteonecrosis.
Bone was considered normal when its architecture was main-
tained and necrosis and inflammation were absent. Bone sam-
ples with findings of osteomyelitis or osteonecrosis were
excluded from the analysis because inflammation and necrosis
can interfere with bone mineralization [13].
Histomorphometry
Measurements were performed by a single experienced oper-
ator (D.C.L.), who was blinded to the clinical status of the pa-
tients. The system for image analysis included an
epifluorescent microscope (Leica DM 2500; Leica Microsys-
tems, Wetzlar, Germany), a digital camera (Leica DFC 420 C;
Leica Microsystems, Wetzlar, Germany), and a computer
equipped with a software for histomorphometric analysis
(Bone version 3.5; Explora Nova, La Rochelle, France).
The histomorphometric values employed for analysis are
the mean of three measurements obtained to approximate a
three-dimensional evaluation. Histomorphometric analysis
and reporting were performed following standard guidelines
[14].The full range of static and dynamic parameters of bone
remodelling was measured, but only those pertinent to test the
study hypothesis are reported in this paper. In particular, the
abnormal deposition of unmineralized osteoid associated with
an impaired (delayed) mineralization process was calculated
using the following parameters: (a) osteoid volume (i.e., the
percentage of unmineralized bone inside a given volume of
bone); (b) corrected osteoid thickness (i.e., the mean corrected
thickness of osteoid seams); and (c) mineralization lag time
(i.e., the average time between osteoid formation and its min-
eralization). An estimate of mineralization lag time per day
was obtained by dividing the osteoid thickness by the adjusted
apposition rate. The adjusted apposition rate was obtained by
multiplying the distance between the two tetracycline labels
(divided by the time between the two tetracycline administra-
tions) with the extent of the labeled surfaces averaged over the
entire osteoid surface (mineralizing surfaces/osteoid surfaces).
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Overall, osteomalacia was diagnosed in the presence of a
mineralization lag time 100 days, a corrected osteoid thick-
ness 12.5 mm, and an osteoid volume 10%, according to
the internationally accepted histomorphometric definition of
osteomalacia [14]. All thickness and depth measurements were
corrected for obliquity by multiplying for /4.
Statistical Analysis
Continuous variables are reported as 25th, 50th, and 75th per-
centiles and minimum and maximum values because of
skewed distributions. Categorical variables are given as the
number or percentage of patients with the characteristic of in-
terest. Between-group comparisons of continuous variables
were performed using the exact Wilcoxon-Mann-Whitney test
and those of categorical variable using Fisher’s exact test. Ex-
act logistic regression was used to evaluate the association be-
tween BRONJ (yes vs. no), mineralization lag time (100
vs. 100 days), corrected mean osteoid thickness (12.5%
vs. 12.5%), and osteoid volume (10% vs. 10%).
Odds ratios (OR) and 95% confidence intervals (CI) were
calculated before and after correction for sex (0 female, 1
male), age (years/10, continuous) and cancer (0  no, 1 
yes). We adjusted for these factors because they could inde-
pendently influence bone metabolism and mineralization.
Statistical analysis was performed on one bone specimen
for each patient. If two specimens per patient were available,
one was randomly chosen for statistical analysis. Even if we
used exact logistic regression, the low number of subjects did
not allow us to adequately model the possibility that one sub-
ject could contribute more than one bone to the analysis (i.e., a
problem of correlated observations) [10]. Statistical analysis
was performed using Stata 12.0 (Stata, College Station, TX)
and StatXact 9 and LogXact 9 (Cytel, Cambridge, MA).
RESULTS
Figure 1 describes the enrollment and selection of cases and
controls for bone histomorphometry. Of 25 potentially eligible
patients, 2 patients were being supplemented with vitamin D
and were excluded from the study. The remaining 23 patients
underwent bone biopsy. One patient who underwent maxillary
resection had histological evidence of osteomyelitis at the mar-
gin of bone resection where the biopsy was taken and was not
considered further. Thus, 22 patients were left for bone histo-
morphometry. Of these, 18 had had their jaws resected and 4
patients had an alveolar bone biopsy from the unaffected jaw.
Of 25 eligible control subjects, 4 were not included because
their bone biopsies showed osteomyelitis. Therefore, 21 con-
trols underwent bone histomorphometry.
Table 1 provides the clinical and histomorphometric mea-
surements of the patients. In the BRONJ group, 18 patients
were women and 4 were men. In the control group, 13 pa-
tients were women and 8 were men. Patients in the BRONJ
group were older than control subjects. The cumulative dose
of zoledronate but not of pamidronate was higher in the
BRONJ group.
Table 2 reports the frequency of osteomalacia as detected
by bone histomorphometry. Two bone specimens, all without
signs of osteomyelitis or osteonecrosis, were available for 14
patients, but only one of them was randomly chosen for statis-
tical analysis. However, the bone specimens not considered for
analysis showed signs of osteomalacia on histomorphometry.
In all, 77% of patients with BRONJ had a mineralization
lag time 100 days as compared with 5% of patients without
BRONJ. In addition, 64% of patients with BRONJ had cor-
rected osteoid thickness 12.5% compared with 5% of pa-
tients without BRONJ. A total of 45% of patients with BRONJ
had osteoid volume10% compared with 5% of patients with-
out BRONJ (Fig. 2).
As determined by exact logistic regression, the odds of
having BRONJ were nearly 60 times higher for patients with a
mineralization lag time 100 days than for those without it
(OR 59, 95% CI: 6–2,977, p .001). These odds were still
very high after correction for sex, age, and cancer (adjusted
OR 62, 95% CI: 8–, p .001). Likewise, the odds of hav-
ing BRONJ were much higher for patients with an osteoid
thickness 12.5% (crude OR  32, 95% CI: 4–1,551, p 
.001; adjusted OR  36, 95% CI: 3–2,657, p  .001) and for
those with an osteoid volume10% (crude OR 16, 95% CI:
2–758, p  .004; adjusted OR  55, 95% CI: 2–7,423, p 
.003).
Control subjects who had been followed up as part of a co-
hort study did not develop any sign of BRONJ up to 1 year after
bone sampling. The four patients who were excluded from the
study because of osteomyelitis were all osteomalacic at histo-
Figure 1. Enrollment and selection of cases and controls for
bone histomorphometry. Abbreviations: BRONJ, bisphospho-
nate-related osteonecrosis of the jaw; NBP, nitrogen-containing
bisphosphonate.
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morphometry and developed clinical and/or radiological signs
of BRONJ within 6 months.
DISCUSSION
NBPs are a mainstay in the treatment of many diseases—
especially metastatic cancer, for which they can have a sub-
stantial impact on a patient’s quality of life. However, the use
of these drugs has been questioned because of their association
with BRONJ. BRONJ is most common in patients treated
with high-dose intravenous cancer medications [3]; it also is
associated with oral surgical procedures, such as tooth ex-
traction [15]. However, the mechanisms of BRONJ are in-
completely understood, so it is difficult to explain why this
disease affects only a small number of patients who use bi-
sphosphonates [16].
Although a cause-effect relationship cannot be inferred
from a single case-control study, our results support the asso-
ciation between osteomalacia and BRONJ development in pa-
tients treated with NBPs. Osteomalacia is characterized by an
impairment of bone mineralization and is commonly caused by
a decrease of the serum calcium-phosphate product, which has
multiple causes. Bone mineralization defects are best quanti-
fied by histomorphometry, but the necessary harvesting of
bone cannot be routinely performed. The availability of a suf-
ficient number of bone biopsies to test the study hypothesis is
a strength of this study. The fact that patients and control sub-
jects were not strictly comparable in terms of age and type of
NBP treatment was due to the limited number of patients that
could be enrolled for the study—not only because BRONJ is
infrequent but also because jawbone surgery in patients with
BRONJ was considered to be unpredictable at the time of the
study [17].
Vitamin D deficiency can lead to osteomalacia in adults
[18, 19]. A recent study has found that vitamin D–depleted rats
taking zoledronate are at greater risk of developing BRONJ
than rats taking zoledronate alone [20]. Thus, it is tempting to
speculate that hypovitaminosis D may also be a risk factor for
BRONJ in humans because it was strongly associated with os-
teomalacia in our study. BRONJ is more frequent in patients
with cancer than in patients with metabolic bone disease [3].
Also, hypovitaminosis D is common in such patients [21]; be-
cause of the well-known association between vitamin D deple-
tion and osteomalacia, vitamin D deficiency may be an
explanation for the high frequency of osteomalacia found in
patients with cancer in our study. Routine use of vitamin D and
calcium supplements during NBP treatment is currently rec-
Table 1. Clinical and histomorphometric characteristics of patients
BRONJ group
(n 22)
Control group
(n 21)
p-value
Percentile
Range
Percentile
Range50th 25th 50th 50th 25th 75th
Age (yrs) 66 65 71 55–84 61 56 64 17–75 .004
Mineralization lag time (days) 157 115 277 7–1370 15 9 21 5–115 .001
Corrected osteoid thickness (mm) 13 12 14 3–15 3 2 4 2–13 .001
Osteoid volume (%) 10 9 10 1–12 3 2 3 1–10 .001
Cumulative dose (mg)
Zoledronate 60 24 100 0–144 8 0 36 0–160 .00
Pamidronate 0 0 2160 0–6120 40 0 1620 0–6,480 .638
Alendronate 0 0 0 0–16,800 0 0 0 0–17,640 NA
Neridronate 0 0 0 0 0 0 0–1,200 NA
Risedronate 0 0 0 0 0 0 0–8,700 NA
p-values obtained by Wilcoxon-Mann-Whitney test.
Abbreviations: BRONJ, bisphosphonate-related osteonecrosis of the jaws; NA, not available.
Table 2. Frequency of osteomalacia
BRONJ
group
(n 22)
Control
group
(n 21) p-value
Mineralization lag time
100 days
.001
No 5 (22.7) 20 (95.2)
Yes 17 (77.3) 1 (4.8)
Corrected osteoid
thickness12.5 mm
.001
No 8 (36.4) 20 (95.2)
Yes 14 (63.6) 1 (4.8)
Osteoid volume10% .004
No 12 (54.5) 20 (95.2)
Yes 10 (45.5) 1 (4.8)
Data are n (%). p-values obtained by Fisher’s exact test.
Abbreviation: BRONJ, bisphosphonate-related osteonecrosis
of the jaws.
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ommended [19]. However, the use of supplements was not
consistently recommended in Italy when our study was per-
formed [22]. This fact helped the recruitment of patients and
allowed us to build up a unique study population, in which we
could measure the association between osteomalacia and
BRONJ.
Our results are at issue with the currently accepted patho-
genetic theory of BRONJ, in which the type of NBP, cumula-
tive dosage, and route of administration are considered to be
the main risk factors [15, 23]. The risk of BRONJ has been pri-
marily linked with the duration of NBP therapy, with an inci-
dence up to 11% after 4 years of intravenous treatment in
patients with cancer [24]. However, other factors may be re-
lated to BRONJ development. The recent observation of
BRONJ in patients treated with denosumab [25], a non-bispho-
sphonate bone resorption inhibitor, suggests that the develop-
ment of BRONJ is not specific to NBPs but common to drugs
inhibiting osteoclast activity. In addition, undiagnosed miner-
alization defects in patients taking drugs that inhibit osteoclast
activity may have a preeminent role in promoting bone necro-
sis. Our results are in line with this finding because osteoma-
lacia was a strong predictor of BRONJ in NBP users.
The fact that a combination of osteomalacia and NBP
treatment may be needed to confer a substantial risk of
BRONJ could explain why BRONJ affects only a small por-
tion of NBP users and why some cancer patients may de-
velop BRONJ even after one or few doses of NBP [26].
Also, high-dose NBPs can induce bone mineralization de-
fects [27, 28]. Of course, it is impossible to say whether os-
teomalacia was caused by or simply associated with NBP
treatment in our patients. It should be nonetheless noted that
our patients without BRONJ were not osteomalacic. This
adds some plausibility to the hypothesis that NBPs affect
bone mineralization in patients with established osteomala-
cia. A recent animal study has shown a negative impact of
NBP on bone mineralization after tooth extraction [29].
Overall, the use of NBPs in subjects with a mineralization
defect could compromise bone repair after traumatic inju-
ries to the oral cavity and facilitate BRONJ.
In one study, patients treated with zoledronate had a nor-
mal bone mineralization and had not developed osteonecrosis
after a median follow-up of 2 years [30]. However, they were
mostly osteoporotic, received yearly infusions of zoledronate,
and were given vitamin D and calcium supplements. It is pos-
sible that the combination of NBPs with undiagnosed osteo-
malacia may increase the risk of BRONJ in patients with
cancer. If our hypothesis of a role for osteomalacia in the
pathogenesis of BRONJ is correct, the role of NBP in the
pathogenesis of BRONJ would be redefined.
CONCLUSION
Osteomalacia is common in patients with BRONJ. This find-
ing may contribute to a better understanding of the pathogen-
esis of this disease and help in the development of strategies to
increase the safety of NBPs.
Figure 2. Histomorphometric evidence of osteomalacia. Goldner’s trichrome-stained (A, C) and tetracycline double-labelled (B, D)
bone specimens obtained from one patient with bisphosphonate-related osteonecrosis of the jaw (BRONJ) (A, B) and one patient without
BRONJ (C, D). (A): The distribution of osteoid within the trabecular surface of a patient with BRONJ in terms of total seams, thickness,
and volume is shown. A great amount of unmineralized osteoid (red) is evenly distributed within the trabeculae (green), which is sug-
gestive of defective bone mineralization. (B): The absent double labelling and the poor, diffuse uptake of the tetracycline labels are shown.
(C): The distribution of osteoid in the trabecular surface of a patient without BRONJ is shown, in terms of total seams, thickness, and
volume. No areas of unmineralized osteoid can be seen within the trabeculae. (D): The characteristic double tetracycline labelling of
normal bone is shown in a patient without BRONJ. Magnification,200.
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